Hepion Pharmaceuticals Stock Price - HEPA

0.02 (0.42%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Hepion Pharmaceuticals Inc HEPA NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
-0.22 -4.45% 4.72 4.66 4.92 4.91 4.94 00:00:04
Bid Price Ask Price Spread Spread % News
4.50 5.02 0.52 10.36% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
813 211,611 $ 4.76 $ 1,007,269 684,570 2.0001 - 8.35
Last Trade Time Type Quantity Stock Price Currency
19:27:06 formt 200 $ 4.74 USD

Hepion Pharmaceuticals Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 17.75M 3.76M -92.84 - 2.81M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Hepion Pharmaceuticals News

Loading Messages....

Latest HEPA Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical HEPA Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week5.025.494.624.85192,722-0.30-5.98%
1 Month5.247.504.515.57915,709-0.52-9.92%
3 Months6.50977.604.515.78639,675-1.79-27.49%
6 Months2.468.352.034.541,077,2362.2691.87%
1 Year3.118.352.00014.46978,9241.6151.77%
3 Years3.118.352.00014.46978,9241.6151.77%
5 Years3.118.352.00014.46978,9241.6151.77%

Hepion Pharmaceuticals Description

Hepion Pharmaceuticals Inc is a United States-based biopharmaceutical company engaged in the development of targeted pharmaceutical therapies for liver disease. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. The company's cyclophilin inhibitor, CRV431 targets multiple biochemical pathways involved in the progression of liver disease.

Your Recent History
Hepion Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.